HC Wainwright Issues Positive Forecast for NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price

NRx Pharmaceuticals (NASDAQ:NRXP) had its target price raised by HC Wainwright from $40.00 to $45.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also issued reports on NRXP. D. Boral Capital reiterated a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, February 17th. Ascendiant Capital Markets reaffirmed a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Finally, Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $38.00.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXP opened at $1.80 on Tuesday. NRx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $3.84. The firm has a 50-day moving average of $2.12 and a 200 day moving average of $2.51. The stock has a market cap of $57.37 million, a P/E ratio of -0.77 and a beta of 1.97.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in NRXP. Ethos Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 3rd quarter valued at $39,000. Sjbenen Advisory LLC bought a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth $41,000. One Wealth Management Investment & Advisory Services LLC increased its position in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after acquiring an additional 12,950 shares during the last quarter. Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals in the fourth quarter valued at about $107,000. Finally, Two Sigma Investments LP boosted its position in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.